Compound E, chemically designated as 209986-17-4 (CAS), represents a significant investigation within the field of Alzheimer's illness research. This γ-secretase modulator was initially developed as a possible therapeutic intervention aimed at reducing the production of amyloid-beta peptides, which are believed to be critical contributors to the f